Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Momelotinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 03 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 05 May 2017 Planned End Date changed from 1 Aug 2021 to 1 Jun 2018.
- 05 May 2017 Planned primary completion date changed from 1 Aug 2021 to 1 Jun 2018.